Featured Press Releases

OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award

OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award

Transposon to share Phase 2 results of TPN-101 for C9orf72-related ALS/FTD at ALS ONE Research Symposium.

Transposon to share Phase 2 results of TPN-101 for C9orf72-related ALS/FTD at ALS ONE Research Symposium.

  • 06 Nov 2024

Transposon Therapeutics, a biotechnology company developing a platform of novel, orally...

Immorta Bio Reports Successful Lung Cancer Growth Inhibition by Senolytic Immunotherapy SenoVax™

Immorta Bio Reports Successful Lung Cancer Growth Inhibition by Senolytic Immunotherapy SenoVax™

RiDYMO® develops a cyclic peptide targeting the

RiDYMO® develops a cyclic peptide targeting the "undruggable" β-catenin in just two months

Eligible Medicare Beneficiaries Living with Obesity Can Now Access Wegovy® Through the Medicare GLP-1 Bridge

Eligible Medicare Beneficiaries Living with Obesity Can Now Access Wegovy® Through the Medicare GLP-1 Bridge

IMAAVY® (nipocalimab-aahu) demonstrated rapid onset and durable hemoglobin response in a pivotal Phase 2/3 study of warm autoimmune hemolytic anemia (wAIHA), a disease with no FDA-approved therapies

IMAAVY® (nipocalimab-aahu) demonstrated rapid onset and durable hemoglobin response in a pivotal Phase 2/3 study of warm autoimmune hemolytic anemia (wAIHA), a disease with no FDA-approved therapies

Abbott receives FDA authorization for the world’s first dual glucose-ketone sensing technology for people with diabetes

Abbott receives FDA authorization for the world’s first dual glucose-ketone sensing technology for people with diabetes

  • Abbott
  • 26 Aug 2026
U.S. FDA Approves Ziihera® (zanidatamab-hrii), With or Without Tislelizumab Plus Chemotherapy, for the First-Line Treatment of HER2-Positive Advanced Gastroesophageal Adenocarcinoma

U.S. FDA Approves Ziihera® (zanidatamab-hrii), With or Without Tislelizumab Plus Chemotherapy, for the First-Line Treatment of HER2-Positive Advanced Gastroesophageal Adenocarcinoma

  • Jazz Pharmaceuticals plc
  • 25 Aug 2026
European Commission Approves DAYBU® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms Associated with Rett Syndrome in the European Union

European Commission Approves DAYBU® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms Associated with Rett Syndrome in the European Union

  • Acadia Pharmaceuticals Inc.
  • 24 Aug 2026
Upsher-Smith Expands Neurology Portfolio with the Launch of Glatiramer Acetate Injection

Upsher-Smith Expands Neurology Portfolio with the Launch of Glatiramer Acetate Injection

  • Upsher-Smith Laboratories, LLC
  • 21 Aug 2026
Dunbar Pharma Brings First Plant-Derived Dronabinol API to the UK Market Through IPS Pharma

Dunbar Pharma Brings First Plant-Derived Dronabinol API to the UK Market Through IPS Pharma

  • Dunbar Pharmaceuticals
  • 18 Aug 2026
Former DePuy Synthes U.S. President Joins Peptilogics Board

Former DePuy Synthes U.S. President Joins Peptilogics Board

  • Peptilogics
  • 18 Aug 2026

Most Popular
August   2026
M T W T F S S
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31            

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.